From Self-sufficiency
Jump to: navigation, search
File:Talampanel skeletal.svg
Systematic (IUPAC) name
(8R)-7-Acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h] [2,3]benzodiazepine
Legal status
Legal status
  • investigational
CAS Number 161832-65-1
ATC code none
PubChem CID 164509
Chemical data
Formula C19H19N3O3
Molar mass 337.372 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Talampanel (GYKI 53405) is a drug which is being investigated for the treatment of epilepsy[1], malignant gliomas[2] and amyotrophic lateral sclerosis (ALS)[3].

It is a noncompetitive antagonist of the AMPA receptor, a type of glutamate receptor in the central nervous system.[4]


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. Luszczki, JJ (2009). "Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions". Pharmacological reports : PR. 61 (2): 197–216. PMID 19443931.  edit
  2. Iwamoto, F. M.; Kreisl, T. N.; Kim, L.; Duic, J. P.; Butman, J. A.; Albert, P. S.; Fine, H. A. (2010). "Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas". Cancer. 116 (7): NA. doi:10.1002/cncr.24957. PMC 2846997Freely accessible. PMID 20143438.  edit
  3. Pascuzzi, R. M.; Shefner, J.; Chappell, A. S.; Bjerke, J. S.; Tamura, R.; Chaudhry, V.; Clawson, L.; Haas, L.; Rothstein, J. D. (2009). "A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis. 11 (3): 091207182741053. doi:10.3109/17482960903307805. PMID 19961264.  edit
  4. Aujla, P. K.; Fetell, M. R.; Jensen, F. E. (2009). "Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model". Epilepsia. 50 (4): 694. doi:10.1111/j.1528-1167.2008.01947.x. PMC 2672962Freely accessible. PMID 19220413.  edit